India
· Delayed Price · Currency is INR Zydus Lifesciences Statistics
Total Valuation
Zydus Lifesciences has a market cap or net worth of INR 979.57 billion. The enterprise value is 979.82 billion.
| Market Cap | 979.57B |
| Enterprise Value | 979.82B |
Important Dates
The next estimated earnings date is Tuesday, February 4, 2025.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | Jul 26, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.31% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 249.07M |
Valuation Ratios
The trailing PE ratio is 22.76.
| PE Ratio | 22.76 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 7.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.51, with an EV/FCF ratio of 30.83.
| EV / Earnings | 22.77 |
| EV / Sales | 4.56 |
| EV / EBITDA | 15.51 |
| EV / EBIT | 17.82 |
| EV / FCF | 30.83 |
Financial Position
The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.27 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.06 |
| Interest Coverage | 72.26 |
Financial Efficiency
Return on equity (ROE) is 19.57% and return on invested capital (ROIC) is 14.80%.
| Return on Equity (ROE) | 19.57% |
| Return on Assets (ROA) | 11.74% |
| Return on Capital (ROIC) | 14.80% |
| Revenue Per Employee | 7.98M |
| Profits Per Employee | 1.60M |
| Employee Count | 26,921 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.75% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +43.75% |
| 50-Day Moving Average | 986.53 |
| 200-Day Moving Average | 1,051.42 |
| Relative Strength Index (RSI) | 47.96 |
| Average Volume (20 Days) | 32,516 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zydus Lifesciences had revenue of INR 214.84 billion and earned 43.03 billion in profits. Earnings per share was 42.65.
| Revenue | 214.84B |
| Gross Profit | 151.81B |
| Operating Income | 53.83B |
| Pretax Income | 57.58B |
| Net Income | 43.03B |
| EBITDA | 61.86B |
| EBIT | 53.83B |
| Earnings Per Share (EPS) | 42.65 |
Balance Sheet
The company has 24.95 billion in cash and 1.91 billion in debt, giving a net cash position of 23.05 billion.
| Cash & Cash Equivalents | 24.95B |
| Total Debt | 1.91B |
| Net Cash | 23.05B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 241.55B |
| Book Value Per Share | 217.00 |
| Working Capital | 68.06B |
Cash Flow
In the last 12 months, operating cash flow was 45.94 billion and capital expenditures -14.16 billion, giving a free cash flow of 31.78 billion.
| Operating Cash Flow | 45.94B |
| Capital Expenditures | -14.16B |
| Free Cash Flow | 31.78B |
| FCF Per Share | n/a |
Margins
Gross margin is 70.66%, with operating and profit margins of 25.06% and 20.03%.
| Gross Margin | 70.66% |
| Operating Margin | 25.06% |
| Pretax Margin | 26.80% |
| Profit Margin | 20.03% |
| EBITDA Margin | 28.79% |
| EBIT Margin | 25.06% |
| FCF Margin | 14.79% |
Dividends & Yields
Zydus Lifesciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 7.05% |
| Buyback Yield | 0.31% |
| Shareholder Yield | 0.31% |
| Earnings Yield | 4.38% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 6, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Oct 6, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |